Biosynex SA
Paris Stock Exchange ALBIO.PA
Biosynex SA EBIT Margin for the year ending December 31, 2023: -37.43%
-
Biosynex SA EBIT Margin for the year ending December 31, 2022 was 15.44%, a -57.80% change year over year.
-
Biosynex SA EBIT Margin for the year ending December 31, 2021 was 36.59%, a 26.11% change year over year.
-
Biosynex SA EBIT Margin for the year ending December 31, 2020 was 29.02%, a 811.33% change year over year.
-
Biosynex SA EBIT Margin for the year ending December 31, 2019 was 3.18%, a 168.07% change year over year.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
Don’t Miss A Beat
| CEO | Mr. Larry Abensur |
| IPO Date | March 28, 2011 |
| Location | France |
| Headquarters | 22 Boulevard Sébastien Brant |
| Employees | 515 |
| Sector | Consumers Staples |
| Industries | |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
Past 5 years
USD 26.53
StockViz Staff
February 7, 2025
Any question? Send us an email